Job Description

Postdoctoral positions in the field of cancer pharmacogenomics are available immediately in Dr. Xifeng Wu’s lab at The University of Texas MD Anderson Cancer Center. Fellows are being recruited for projects aimed at identifying biomarkers for the prediction of cancer treatment outcomes by integrating genetic variation information with clinical and epidemiological data utilizing our well-characterized patient populations and extensive collection of biospecimens. Dr. Wu’s research group successfully executes contemporary epidemiologic strategies across the cancer continuum by employing advanced, state-of-the-art equipment including high- and mid-throughput assay platforms for genotyping, copy number analysis, next-generation sequencing, whole-genome expression profiling, as well as microRNA and metabolome profiling. Our capabilities include single-cell and high-content analysis, FISH, telomere length and mitochondrial DNA analysis, and other cell-based phenotypic studies.

The overarching goal of Dr. Wu’s translational research program is to construct comprehensive, clinically applicable risk prediction models along the entire cancer continuum, from etiology to screening, prognosis, treatment response and survivorship. To accomplish the program’s objectives, my laboratory practices multidisciplinary research that bridges the fields of basic science, epidemiology, biostatistics, and clinical research. We devise integrative strategies that enable risk assessment, early detection and delineation of early- and late-stage clinical outcomes. Our investigations channel towards identification and validation of clinically useful prognostic and predictive biomarkers, and discovery of molecular targets with therapeutic potential. Assimilation of biomarkers with epidemiological, clinical, phenotypic, and genetic information enables development of accurate and reliable personalized cancer risk prediction models that inform clinical care and empower clinical risk stratification along the cancer care continuum. Our multifaceted and highly innovative research has yielded novel and significant findings across malignancies, including in bladder cancer, lung cancer, renal cell carcinoma, and gastrointestinal cancer.

Successful applicants will have great opportunities to collaborate with an interdisciplinary team of biologists, epidemiologists, statisticians, and clinicians, and to develop multidisciplinary knowledge and techniques in molecular and cellular biology, epidemiology, statistics, genetics, genomics, and cancer medicine.

We seek highly motivated, enthusiastic individuals who have a Ph.D. and/or M.D. degree with less than 2 years of postdoctoral experience in biochemistry, molecular biology, cellular biology, genetics, or related fields. Applications, including curriculum vitae, contact information for three references, and a brief summary of past accomplishments should be sent by regular mail or email to: Shirley Freeman, Department of Epidemiology, Division of Cancer Prevention, The University of Texas MD Anderson Cancer Center, 1155 Pressler Blvd. Box 1340, Houston, TX, 77030. Email: SMFreeman1@mdanderson.org
 
M. D. Anderson Cancer Center is an equal opportunity employer and does not discriminate on basis of race, color, national origin, gender, sexual orientation, age, religion, disability or veteran status except where such distinction is required by law. All positions at The University of Texas M. D. Anderson Cancer Center are security sensitive and subject to examination of criminal history record information. Smoke-free and drug-free environment.
 
Contact: Shirley Freeman
Epidemiology
The University of Texas M. D. Anderson Cancer Center
1155 Pressler Blvd.
Houston, TX 77030
United States
Email: smfreeman1mdanderson.org
Employer's Web Site: Visit employer's website
得克薩斯大學(xué)MD安德森癌癥中心
 
職位名稱：癌癥藥理學(xué)博士后
招聘人數(shù)：4014855
發(fā)布日期：2014年9月2日
報(bào)名截止日期：不限滿為止

 
職位描述

在腫瘤藥物基因組學(xué)領(lǐng)域的博士后職位，立即可在西峰吳博士的實(shí)驗(yàn)室在得克薩斯大學(xué)MD安德森癌癥中心的大學(xué)。研究員正在招募，旨在確定生物標(biāo)記用于癌癥治療結(jié)果的預(yù)測與臨床和流行病學(xué)資料利用我們良好的特點(diǎn)的患者人群和生物標(biāo)本的廣泛收集整合的遺傳變異信息的項(xiàng)目。吳博士的研究小組采用先進(jìn)設(shè)備，最先進(jìn)的先進(jìn)設(shè)備，包括高，中通量檢測平臺，用于基因分型成功執(zhí)行過癌癥連續(xù)當(dāng)代流行病學(xué)策略，拷貝數(shù)分析，新一代測序，全基因組表達(dá)譜，以及小分子RNA和代謝組分析。我們的能力，包括單細(xì)胞和高內(nèi)涵分析，F(xiàn)ISH，端粒長度和線粒體DNA的分析，和其它細(xì)胞系的表型的研究。

吳醫(yī)生的翻譯研究項(xiàng)目的總體目標(biāo)是建設(shè)綜合性，臨床應(yīng)用風(fēng)險(xiǎn)預(yù)測模型在整個(gè)癌癥連續(xù)，從病因?qū)W篩查，預(yù)后，治療反應(yīng)和存活率。為了實(shí)現(xiàn)該計(jì)劃的目標(biāo)，我的實(shí)驗(yàn)室實(shí)行多學(xué)科研究的橋梁基礎(chǔ)科學(xué)，流行病學(xué)，生物統(tǒng)計(jì)學(xué)和臨床研究領(lǐng)域。我們制定綜合戰(zhàn)略，使風(fēng)險(xiǎn)評估的早期和晚期階段的臨床結(jié)果，及早發(fā)現(xiàn)和圈定。我們的研究引向鑒定和臨床價(jià)值的診斷和預(yù)測生物標(biāo)記物驗(yàn)證和發(fā)現(xiàn)的分子靶標(biāo)具有治療潛力。生物標(biāo)志物與流行病學(xué)，臨床，表型和遺傳信息的同化使的告知臨床護(hù)理和授權(quán)以及癌癥治療的臨床連續(xù)危險(xiǎn)分層準(zhǔn)確而可靠的個(gè)性化癌癥風(fēng)險(xiǎn)預(yù)測模型的發(fā)展。我們的多面性和高度創(chuàng)新的研究已經(jīng)跨越惡性腫瘤產(chǎn)生新穎顯著發(fā)現(xiàn)，包括膀胱癌，肺癌，腎癌和胃腸道癌癥。

成功的申請者將有很大的機(jī)會，生物學(xué)家，流行病學(xué)家，統(tǒng)計(jì)學(xué)家和臨床醫(yī)生組成的跨學(xué)科團(tuán)隊(duì)合作，發(fā)展的分子和細(xì)胞生物學(xué)，流行病學(xué)，統(tǒng)計(jì)學(xué)，遺傳學(xué)，基因組學(xué)和癌癥醫(yī)學(xué)多學(xué)科的知識和技巧。

我們尋求積極進(jìn)取，熱心人士誰擁有博士學(xué)位和/或MD學(xué)位與不到2年的生物化學(xué)博士后經(jīng)歷，分子生物學(xué)，細(xì)胞生物學(xué)，遺傳學(xué)，或相關(guān)領(lǐng)域。應(yīng)用，包括個(gè)人簡歷，聯(lián)系方式為三個(gè)引用，和過去的成就進(jìn)行了簡要總結(jié)應(yīng)該通過普通郵件或電子郵件發(fā)送到：雪莉·弗里曼，流行病學(xué)研究室，癌癥預(yù)防，得克薩斯大學(xué)MD安德森癌癥中心的大學(xué)部， 1155普雷斯勒大道。盒1340，休斯敦，得克薩斯州，77030.電子郵件：SMFreeman1@mdanderson.org
 
  
MD安德森癌癥中心是一個(gè)機(jī)會均等的雇主，基于種族，膚色，國籍，性別，性傾向，年齡，宗教，殘疾或退伍軍人身份的基礎(chǔ)不歧視，除非這種區(qū)分法律要求。在得克薩斯大學(xué)MD安德森癌癥中心的大學(xué)所有的位置都是檢查犯罪記錄的信息安全敏感的話題。無煙和無毒環(huán)保。
 
聯(lián)系方式：雪莉·弗里曼
流行病學(xué)
得克薩斯大學(xué)MD安德森癌癥中心的大學(xué)
1155普雷斯勒大道。
休斯頓，德克薩斯州77030
美國
電子郵件：smfreeman1@mdanderson.org

為防止簡歷投遞丟失請抄送一份至：boshijob@126.com（郵件標(biāo)題格式：應(yīng)聘職位名稱+姓名+學(xué)歷+專業(yè)+中國博士人才網(wǎng)）